China Resources Double-Crane Receives Drug Registration Certificates for Injectable Isavuconazonium Sulfate and Other Products
November 4, 2026
Source: drugdu
28
News summary: On November 3, China Resources Double-Crane announced that it and its subsidiaries, Xi’an Jingxi Double-Crane and CR Double-Crane Xiangzhong Pharmaceutical, had received three drug registration certificates from China’s NMPA.
Injectable isavuconazonium sulfate treats invasive aspergillosis, mucormycosis and related infections in adults and children aged one year or older. Sorbitol–mannitol irrigation solution is used during transurethral prostate resection and other urological procedures. Brexpiprazole tablets treat schizophrenia in adults.
Source: URL: https://finance.eastmoney.com/a/202611033920320477.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Azithromycin Dispersible Tablets (0.25g) from Shijiazhuang No. 4 Pharmaceutical Group have passed the quality assessment. November 4, 2026
- The stock price plummeted 90% after the Phase 2 clinical trial failed November 4, 2026
- United Imaging Healthcare enters a period of transition. November 4, 2026
- ST Humanwell Secures German BfArM Marketing Authorization for Fentanyl Citrate Injection November 4, 2026
- ST Nuotai’s Fulvestrant Injection ANDA Receives FDA Approval, Its First Formulation Approved in the U.S November 3, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
